Clin Exp Vaccine Res.  2013 Jul;2(2):140-143. 10.7774/cevr.2013.2.2.140.

Varicella outbreak in the patients during group therapy: seroprevalence in a healthcare system during breakthrough varicella occurrence

• Park CS
• Kim DS
• Kim KH

• KMID: 2167725
• DOI: http://doi.org/10.7774/cevr.2013.2.2.140

Abstract

PURPOSE
There are different principles regarding varicella vaccination depending on social requirements. This study was performed to report a case of breakthrough chickenpox outbreak among a group of people in the healthcare center and also evaluate the seroprevalence of patients who have been managed with chronic neurological diseases in this center.
MATERIALS AND METHODS
We included patients diagnosed with varicella in April 2009 as an index cases and investigated the past history for chickenpox and the varicella-specific IgG. Sixty-two patients (children) and 156 healthcare workers who may have had possible contact with the index cases were also investigated for.
RESULTS
We investigated the seroprevalence of 62 patients not affected by the outbreak. The varicella vaccination rate in children was 90.3%. Sixty-one point three percent of all patients were seropositive and 63.6% of these patients were aged between 12 and 23 months and 87.5% were aged between 24 and 35 months. Seropositive rate was decreased for patients aged between 36 and 59 months while the seropositive prevalence has increased for patients over 5 years old. Over 90% of the adults investigated were seropositive. IgG seronegative despite vaccination was 32.1% (18 persons).
CONCLUSION
Breakthrough varicella outbreak can have huge impact in healthcare centers with affiliated group housing. We need to investigate vaccination status and immunogenicity according to ages and reflect appropriately on vaccination policy taking into consideration of social and medical requirements in the local area.

Keyword

Breakthrough; Chickenpox; Varicella; Seroprevalence; Immunization

MeSH Terms

Adult
Aged
Chickenpox
Child
Delivery of Health Care
Housing
Humans
Immunization
Immunoglobulin G
Prevalence
Seroepidemiologic Studies
Vaccination
Immunoglobulin G

Figure

• 

  Fig. 1 Varicella cases by dates after development of symptoms according to patients.

• 

  Fig. 2 The curve of varicella seroprevalence rate by ages.

Reference

1. Gershon AA, Takahashi M, Seward JF. Varicella vaccine. In : Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Philadelphia: Saunders Elsevier;2013. p. 837–869.

2. Vazquez M, LaRussa PS, Gershon AA, Steinberg SP, Freudigman K, Shapiro ED. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med. 2001; 344:955–960.

3. Marin M, Guris D, Chaves SS, Schmid S, Seward JF. Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56:1–40.

4. Sadzot-Delvaux C, Rentier B, Wutzler P, et al. Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis. 2008; 197:Suppl 2. S185–S190.

5. The Korean Pediatric Society. In : Lee HJ, editor. Varicella vaccine. Immunization guideline. 7th ed. Seoul: The Korean Pediatric Society;2012. p. 121–132.

6. White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J. 1992; 11:19–23.

7. Clements DA. Modified varicella-like syndrome. Infect Dis Clin North Am. 1996; 10:617–629.

8. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA. 2004; 292:704–708.

9. Michalik DE, Steinberg SP, Larussa PS, et al. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis. 2008; 197:944–949.

10. Marin M, Watson TL, Chaves SS, et al. Varicella among adults: data from an active surveillance project, 1995-2005. J Infect Dis. 2008; 197:Suppl 2. S94–S100.

11. Salzman MB, Garcia C. Postexposure varicella vaccination in siblings of children with active varicella. Pediatr Infect Dis J. 1998; 17:256–257.

12. Black S, Ray P, Shinefield H, Saddier P, Nikas A. Lack of association between age at varicella vaccination and risk of breakthrough varicella, within the Northern California Kaiser Permanente Medical Care Program. J Infect Dis. 2008; 197:Suppl 2. S139–S142.

13. Seward JF, Zhang JX, Maupin TJ, Mascola L, Jumaan AO. Contagiousness of varicella in vaccinated cases: a household contact study. JAMA. 2004; 292:704–708.

14. Tugwell BD, Lee LE, Gillette H, Lorber EM, Hedberg K, Cieslak PR. Chickenpox outbreak in a highly vaccinated school population. Pediatrics. 2004; 113(3 Pt 1):455–459.

15. Lee BR, Feaver SL, Miller CA, Hedberg CW, Ehresmann KR. An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis. 2004; 190:477–483.

16. Vazquez M, LaRussa PS, Gershon AA, et al. Effectiveness over time of varicella vaccine. JAMA. 2004; 291:851–855.

17. Vazquez M, Shapiro ED. Varicella vaccine and infection with varicella-zoster virus. N Engl J Med. 2005; 352:439–440.

18. Chaves SS, Gargiullo P, Zhang JX, et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med. 2007; 356:1121–1129.

19. American Academy of Pediatrics Committee on Infectious Diseases. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine two-dose varicella immunization schedule [Internet]. Elk Grove Village: American Academy of Pediatrics;2007. cited 2007 Apr 16. Available from: http://aapredbook.aappublications.org/site/news/Varicella-040907.pdf.